Consano Bio
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
100 Summit Dr, Burlington, Massachusetts...Phone Number
(617) 798-4559Website
www.consanobio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Consano Bio
Consano Bio is developing a first-in-category biologic therapeutic, C-1101, aimed at treating painful and debilitating orthopedic conditions, particularly chronic lumbosacral radiculopathy. The therapy utilizes highly potent cytokines to create an anti-inflammatory microenvironment and promotes local cell proliferation through platelet growth factors. The company focuses on pioneering a new therapeutic modality in the field of pain management and orthopedic healing. They cater to patients suffering from specific orthopedic ailments needing advanced treatment options.Explore more
Consano Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Consano Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Consano Bio
Consano Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Consano Bio has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Consano Bio recently announced quarterly report
Check out if Consano Bio is spiking on competitors!
Check if Consano Bio has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Consano Bio launches new products
Click to see if Consano Bio had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Consano Bio as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Consano Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Consano Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Consano Bio.
Consano Bio financials insights
Gather financial insights about Consano Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Stock/Share Issuance
$34.8M
Most Recent Scoops
Project
Legal Affairs, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Funding
Funding
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Event
Consano Bio News & Media
Consano Bio Receives FDA Investigational New Drug Clearance to Expand the C-1101 Chronic Sciatica Clinical Development Program into the United States
C-1101 is a potential first-in-class, disease-modifying, non-opioid therapy designed to address the underlying biology of chronic sciatica BURLINGTON, Mass., July 20, 2026 /PRNewswire/ -- Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics designed to...Consano Bio Highlights Scientific Advisory Board for C-1101, a Potential First-in-Class, Non-Opioid Therapy in Development for Chronic Sciatica
Board brings deep expertise in pain medicine, regulatory strategy, biologics manufacturing, and hematological research to guide the company's first-in-class program Advisory support includes former U.S. Surgeon General Jerome Adams, M.D., MPH, and interventional orthopedics pioneer...Consano Bio to Present Clinical Development of C-1101 for Chronic Sciatica at 2026 BIO International Convention
The company recently announced initiation of a Phase 1 trial for C-1101, a potential first-in-class, non-opioid therapy for chronic sciatica BURLINGTON, Mass., June 10, 2026 /PRNewswire/ -- Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to...Consano Bio Initiates Phase 1 Clinical Trial of C-1101, a Potential First-in-Class, Non-Opioid Therapy for Chronic Sciatica
First patient successfully dosed in a randomized, controlled Phase 1 trial evaluating C-1101 in patients with chronic sciatica C-1101 is a novel biologic designed as a disease-modifying treatment targeting the underlying cause of chronic, painful lumbosacral radiculopathy (chronic...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Consano Bio
Sign Up For FreeTo access detailed company insights
Consano Bio is developing a first-in-category biologic therapeutic, C-1101, aimed at treating painful and debilitating orthopedic conditions, particularly chronic lumbosacral radiculopathy. The therapy utilizes highly potent cytokines to create an anti-inflammatory microenvironment and promotes local cell proliferation through platelet growth facto... Read More
